Sean C. Flynn, serving as the Chief Legal Officer for Vericel Corp (NASDAQ:VCEL), has disclosed a series of transactions involving the company's common stock. According to a Form 4 filing lodged with the Securities and Exchange Commission on June 26, 2026, Mr. Flynn executed a sale of 15,000 shares. The disposal was carried out at a price of $45.64 per share, resulting in total proceeds of $684,600.
These sales were processed under the guidelines of an automatic trading plan established pursuant to Rule 10b5-1. Mr. Flynn initially adopted this plan on December 2, 2025. The execution of the trade occurred at a price point proximate to the stock's 52-week high of $46.62. At the time of the filing, the shares were trading at $44.46. The equity has demonstrated an 11.6% return over the preceding week, alongside notable gains recorded over recent months.
In a concurrent transaction detailed in the filing, Mr. Flynn acquired 15,000 shares of Vericel common stock. This acquisition was facilitated through the exercise of stock options priced at $16.25 per share, amounting to a total value of $243,750. These options, which grant the right to purchase shares, became exercisable on November 4, 2020. The vesting schedule for these options is contingent upon Mr. Flynn's continued service to the company. The options carry an expiration date of November 4, 2029.
Following the completion of these transactions, Mr. Flynn's direct holdings in Vericel common stock stand at 1,647 shares. These holdings encompass shares acquired through the Issuer's 2015 Employee Stock Purchase Plan. Furthermore, Mr. Flynn retains a position of 55,000 derivative shares in the form of stock options.
Market analysis from InvestingPro suggests that Vericel appears undervalued at current trading levels. The platform identifies the stock as trading near its 52-week high among a total of 18 ProTips available. Comprehensive analysis of Vericel is accessible through a Pro Research Report, which covers this equity alongside over 1,400 other US equities.
Vericel Corp OrdFollowAnalyze VCELIncluded in our AI-picked strategies·Review strategies44.46▼-0.61(-1.35%)Closed·15:59:59·USD44.490.00(0.00%)After Hours·16:11:251D1W1M6M1Y5YMaxCreated with Highcharts 11.4.814:0015:0016:0017:0018:0019:00434445Analyze VCEL
In broader corporate developments, Vericel Corporation reported a robust start to fiscal 2026. First-quarter earnings and revenue figures exceeded market expectations. The company achieved an earnings per share (EPS) of -$0.12, which surpassed the anticipated figure of -$0.15. Revenue was reported at $68.4 million, outperforming the forecast of $63.7 million.
These financial results highlight a positive trajectory for Vericel, as the company continues to deliver above analyst projections. The developments have garnered attention from market analysts, contributing to a favorable outlook for the company's financial health. Investors are closely monitoring these updates as Vericel progresses through the fiscal year. These recent developments underscore the company's ability to navigate market conditions effectively.